Keryx Biopharmaceuticals News
StreetInsider.com Pre-Open Movers 6/19: (PLX) (CYTK) (ADBE) Higher; (OSH) (VNDA) (TTEK) Lower (more...)Street Insider 9:30 AM
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira PharmaceuticalsPR Newswire Jun 17
NEW YORK, June 17, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: ...
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements andJun 13
In a bubbly year for the biotech sector, these five stocks stand out over the rest.
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial SJun 4
InPlay: Keryx Biopharma announces Zerenex Phase 3 data presented at the 2013 World Congress of Nephrology; Dr. Lewis' presentation confirmed that Zerenex met the pre-defined primary and key secondary endpointsJun 3
Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of NephrologyPR Newswire Jun 3
NEW YORK, June 3, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex ...
Investors considering a purchase of Keryx Biopharmaceuticals Inc. shares, but tentative about paying the going market price of $8.14/share, might benefit from considering selling puts among the alternative strategies at their disposal.